الصفحة الرئيسية>>Signaling Pathways>> Microbiology & Virology>> Bacterial>>WQ3810 (KPI-10 free base)

WQ3810 (KPI-10 free base) (Synonyms: KPI-10 free base)

رقم الكتالوجGC32370

WQ3810 (قاعدة خالية من KPI-10) عبارة عن فلوروكينولون نشط عن طريق الفم ، مع أنشطة قوية مضادة للجراثيم.

Products are for research use only. Not for human use. We do not sell to patients.

WQ3810 (KPI-10 free base) التركيب الكيميائي

Cas No.: 888032-58-4

الحجم السعر المخزون الكميّة
1mg
3640٫00
متوفر
5mg
8530٫00
متوفر
10mg
15196٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

WQ3810 is an orally active fluoroquinolone, with potent antibacterial activities.

WQ-3810 shows potent activity against A. baumannii, including MDR isolates, with MIC90 of 1 mg/L, more than eight-fold higher than that of ciprofloxacin (64 mg/L) and levofloxacin (8 mg/L). WQ-3810 also exhibits inhibitory effects on E. coli and S. pneumoniae, including FQR isolates, with MIC90 of 4 mg/L and 0.06 mg/L, respectively. WQ-3810 is the most potent among the fluoroquinolones tested against meticillin-resistant Staphylococcus aureus (MRSA) and Neisseria gonorrhoeae, including FQR isolates[1].

[1]. Kazamori D, et al. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens. Int J Antimicrob Agents. 2014 Nov;44(5):443-9.

مراجعات

Review for WQ3810 (KPI-10 free base)

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for WQ3810 (KPI-10 free base)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.